CDH17 and digestive system cancer: CDH17 has been extensively studied as a promising biomarker and therapeutic target for digestive system cancers, including gastric, pancreatic, and colorectal cancers.[11, 12] However, concerns have been raised regarding potential off‐target effects on normal intestinal epithelia, which also express CDH17 protein.